NASDAQ:PCVX
Vaxcyte, Inc. Stock News
$75.45
+3.82 (+5.33%)
At Close: May 16, 2024
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
04:01pm, Thursday, 04'th Jan 2024
-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability
-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20 ® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met
Vaxcyte Appoints Jacks Lee to Board of Directors
08:30am, Tuesday, 28'th Nov 2023
SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacter
-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company's Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Righ
-- VAX-31, a 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, is the Broadest-Spectrum PCV to Enter the Clinic -- -- Topline Safety, Tolerability and Immunogenicity Data Expected in Second Ha
Vaxcyte to Present at Upcoming Investor Conferences
04:05pm, Tuesday, 31'st Oct 2023
SAN CARLOS, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
04:05pm, Tuesday, 19'th Sep 2023
SAN CARLOS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
Strong Financials And Pipeline Position Vaxcyte For Success
06:34pm, Thursday, 17'th Aug 2023
Vaxcyte, Inc. is a clinical-stage vaccine company developing high-fidelity vaccines for bacterial diseases. The company's Q2 2023 earnings report shows significant growth in cash and investments, indi
5 Biotech Stocks to Buy as Industry Prospects for 2H23 Look Good
10:32am, Tuesday, 13'th Jun 2023
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position PCVX, PTGX, LGND
Vaxcyte to Present at the Jefferies Healthcare Conference
04:05pm, Thursday, 01'st Jun 2023
SAN CARLOS, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequ
Wall Street Analysts Think Vaxcyte, Inc. (PCVX) Could Surge 33.33%: Read This Before Placing a Bet
11:05am, Monday, 29'th May 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 33.3% in Vaxcyte, Inc. (PCVX). While the effectiveness of this highly sought-after metric is questionable, the
Vaxcyte: Positive Phase 2 Results Elevate Confidence In VAX-24's Potential
08:20am, Wednesday, 17'th May 2023
Vaxcyte is emerging as a leader in vaccine innovation, leveraging high-fidelity vaccines to combat bacterial diseases. The company's lead candidate, VAX-24, demonstrated robust immune responses and a
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
04:05pm, Wednesday, 03'rd May 2023
SAN CARLOS, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseque
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
08:07am, Thursday, 20'th Apr 2023
Where is the current bull market? All indications would be that it's in biotech!
Vaxcyte (PCVX) Up on Pneumococcal Conjugate Vaccine Data
02:28pm, Tuesday, 18'th Apr 2023
Vaxcyte (PCVX) announces positive results from the mid-stage study of its 24-Valent pneumococcal conjugate vaccine candidate, VAX-24, in adults aged 65 and older.